Articles About Biotech Investing

The Top 3 Biotech Stocks to Own (One Could Bring You 571% Gains This Year)

0 | By Michael A. Robinson

New investment opportunities are cropping up in every corner of the tech sector. But sorting the winners that could bring you a life-changing windfall from the wannabes that could tank your portfolio?

That’s why you joined Strategic Tech Investor.

I’ve been investing in tech companies and reporting on this sector for decades. And after 36 years of experience with Silicon Valley, working as a consultant, advisor, and board member in the world of high-tech venture capital, you could say I’ve learned a thing or two about what those winners look like (and how to identify them).

One of the things I watch for is where the money moves. Where are institutional investors placing their bets? It’s not always obvious – they keep quiet when there’s big money on the line.

So when I saw that major biotech firms had amassed a $1.7 trillion war chest for what could be a record mergers and acquisition (M&A) spree in 2022, I couldn’t ignore the potential for profits.

To help you get ahead of this flood of cash, I’ve been looking for the best and brightest biotech stocks to bring you – and I have three huge opportunities to share with you today.

Each of these picks gives you a unique way to play the biotech sector as it continues to heat up – and the third could even bring you 571% gains this year…

Future Tech Watchlist: The $12 Billion Company Targeting Dozens of Orphan Drugs

0 | By Michael A. Robinson

Watch the biotech sector – that’s what we told you in Monday’s First Read. Major biotech firms have amassed a $1.7 trillion war chest ahead of what could be a record M&A spree in 2022, according to Fierce Biotech, and it’s only a matter of time before the money starts flowing.

And with this space heating up, there is one name that needs to be on your moneymaking watchlist as it works overtime on breakthrough drugs that could help cure some of the world’s most devastating medical conditions.

Here’s what I mean.

To date, there are over 7,000 identified rare diseases, including 200 rare cancers. Only 500 of those diseases are currently treatable – meaning the vast majority of the 300 million-plus people worldwide living with a rare disease have no way to get better. The number of people with one of these sicknesses is the equivalent to the third-largest country in the world. Many of them are children.

Until about 40 years ago, pharmaceutical companies had no incentive to develop treatments for these diseases other than out of the goodness of their heart. The cost to bring a drug to market far outweighed the profits that could be made from such a small fraction of society.

But everything changed with the Orphan Drug Act of 1983.

To incentivize companies to develop treatments for rare conditions that affect fewer than 200,000 patients, this new orphan drug program created a path for them to bring drugs to market up to 12X faster with significantly lower research and development (R&D) costs.

So, we’re talking tax credits, grants, discounted registration fees, and exclusive marketing rights to their orphan drug for up to seven years – enough to inject about $100 million into a company’s value, even before clinical trials.

You’re familiar with two of the leaders in orphan drug development, Pfizer Inc. (PFE) and AbbVie Inc. (ABBV).

But today, I want to show you another company making unusually large waves in this space with 55 orphan drugs in the pipeline…

Earn a Strong Dividend without Sacrificing Growth with This Biotech Stock

0 | By Michael A. Robinson

You could forgive CEO Rick Gonzalez if he feels like gloating these days.

Back in June 2019, he announced that his biopharmaceutical firm was paying $63 billion to buy an Irish drug firm.

Gonzalez patiently explained to investors that the huge transaction would have a profound impact on his firm’s growth story.

Wall Street strongly disagreed, and Gonzalez watched as the stock sank 15% in a single session, erasing almost $20 billion in market value.

No doubt some of that selloff stemmed from fears that the deal would jeopardize the juicy dividend this firm had been paying for years.

Well, as the saying goes, look who’s laughing now – because the transaction was nothing short of transformative.

Fact is, the stock boasts a very nice yield of 4% and has beat the broad market by some 49%.

As the biotech sector heats up, let me show you a strong dividend-paying stock like this one is a great way to play today’s market…

Vaccine Profits Will Only Grow From Here, and You Can Claim a Piece of Them

0 | By Michael A. Robinson

Delta Variant on the Rise

Please don’t think I’m being flip. Even my friends who had both doses of the FDA approved vaccine have experienced breakthrough cases.

I’m sharing this with you not to cause alarm but to alert you to a great way to invest in the $753 billion biotech sector.

You may have heard about a key medical panel advising the US government has already called for Covid booster shots for some segments of the population after this first wave of vaccinations.

What’s more, biotech executives are now proposing to use gene-based vaccines to fight the seasonal flu. Before the pandemic, roughly 45% of the US population got flu shots every year. Doubtless, now with greater awareness of the risks, that number will grow.

More people protecting themselves against infectious diseases is great for the world and even better for a biotech leader that pioneered the entire genetic approach that received approval for a Covid vaccine in record time.

The firm recently crushed Wall Street forecasts on the back of a stunning sales increase of 6,400% with still more upside ahead…

Wall Street is Counting Out the Biggest Breakthrough in Medicine – Here’s How to Make Their Mistake into Your Gain

0 | By Michael A. Robinson

When Wall Street overreacts and goes right, you can make a fortune by avoiding the noise and going in the opposite direction.

In the latest edition of wild overreactions, Cathie Wood, the top-notch ETF manager of Ark Investment Management, received some flak from The Wall Street Journal.

I’ll have more on that in just a bit and why it is totally off the mark.

But make no mistake. Wood has an uncanny eye for finding breakout stocks with a market-beating track record to prove it.

One particular feather in Wood’s cap is an ETF that she runs focusing on the cutting-edge field of genomics, a tech that basically didn’t exist just a decade ago.

Without genomics, we wouldn’t have been able to understand the structure of the coronavirus. Not only that, but the first two vaccines approved both relied on a hot new segment of genomics.

And this is an industry that is projected to multiply from $18.85 billion in 2019 to $82.60 billion in 2027, according to Fortune Business Insights. That’s more than 300% growth in less than a decade.

I’ll give you more details in a moment. But first, I want to point out the sizzling returns that Wood has amassed.

Over roughly the past year, Wood’s fund beat the market by a stunning 471%.

Let me show you why this play is just getting started…

It’s Not Too Late to Play the Covid Vaccine Rollout – All Thanks to This Company

0 | By Michael A. Robinson

If you missed the chance to get in early on coronavirus vaccine stocks, don’t worry.

It’s not too late.

Of course, investing in a “pure-play” at this point in the market cycle dogged by so many conflicting headlines could be pretty risky.

Any resistance from the FDA for a new vaccine and the maker’s stock could get pummeled.

I’ve seen it happen before and I can nearly guarantee it will happen again.

That’s why I’m excited to reveal a biotech supply firm that’s involved in developing and producing coronavirus vaccines.

Even better, this is a rare twofer – this supply firm isn’t just focused on new vaccines. It works with a huge swath of the biotech sector.

Its forte puts it squarely in a market that is on pace to be worth $456.8 billion.

Not only that, but this savvy leader is on pace to double its earnings in the next two years…

This Tech Is About to Save Tourism – And Open A Massive Moneymaking Window

0 | By Michael A. Robinson

I’ve mentioned in the past that tech saved the economy. Letting people do things like work, shop, and even visit the doctor, all online, has made it possible to live with shutdowns and quarantines.

And now, tech is about to pull an encore and save an entirely new sector: tourism.

You see, tourism happens to be one industry that couldn’t just be moved online. Forbes was reporting losses close to $1 trillion, and 100 million threatened jobs, as far back as August.

A talk I had recently during my own vacation to Mexico really shed a light on the need for a high-tech solution. And, in this case, I’m talking about biotech

Oscar, the driver who picked us up at the airport, quickly brought the discussion around to the topic that seems to be on everyone’s mind in this tourist community – The Vaccines.

Because the tourist economy here depends on a healthy U.S., Oscar was very excited about the recent news of three COVID breakthroughs.

“When the United States get the flu,” Oscar said, “Mexico gets a heart attack.”

Oscar’s not the only one following the biotech breakthroughs. Millions of investors back home are looking for ways to cash in on it all.

With that in mind, today I want to show you a great way to profit from the entire vaccine space with a market-crushing winner…

The Latest Nobel Prize in Chemistry Is Hiding A Massive Moneymaking Opportunity

0 | By Michael A. Robinson

When it comes to scientific breakthroughs, the only thing better than a Nobel Prize is a Nobel Prize with its own hidden way to beat the market.

And that’s exactly the opportunity I’m presenting to you today.

It comes to us from the field of gene editing, which actually allows doctors to edit material in human DNA to combat disease.
As a biotech investor, I have followed this field for many years.

While it stretches back to the 1970s, two women recently shared a Nobel Prize in Chemistry for turning the field on its head.

They developed what’s known as Crispr-Cas9, which allows genomic editing at the embryonic level. The Nobel committee described the science as “rewriting the code of life.”

The market for direct use of this platform is growing at 16% per year and will soon be worth roughly $10 billion.

And there is a firm pioneering this field that is beating the broad market by more than 45%…